Search      Advanced Search

UK-Watford: medical equipments

Contract Award

General Information
Country:   United Kingdom
City/Locality:   WATFORD
Notice/Contract Number:   eu:254542-2008
Publication Date:   Oct 4, 2008
Buyer:   NHS BLOOD AND TRANSPLANT (NHSBT)
Original Language:   English

Contact Information
Address:   NHS BLOOD AND TRANSPLANT (NHSBT)
WATFORD
United Kingdom
Web Site:   www.blood.co.uk

Goods, Works and Services

 

Original Text

      view in:

Notice Type: 2180
-
Contract award
Regulation of Procurement: European Communities
EU Official Journal Publication: 193/2008
, #
254542-2008
Referenced Document Number: 135802-2007
Contract Nature: Supply contract
Procedure Type: Contract awards
Type of Bid Required: Not applicable
Awarding Criteria: The most economic tender
Successful Bidder: NAME AND ADDRESS OF ECONOMIC OPERATOR TO WHOM THE CONTRACT HAS BEEN
AWARDED: MacoPharma (UK) Ltd, 8th Floor Regal House 70 London Road,
UK-Twickenham TW1 3QS. E-mail: belinda.larby@macopharma.co.uk.

Summary:
CONTRACT AWARD NOTICE
Supplies
SECTION I: CONTRACTING AUTHORITY
I.1) NAME, ADDRESSES AND CONTACT POINT(S): NHS Blood and Transplant
(NHSBT), Oak House Reeds Cresecent, Attn: Marnie Watkins, UK-Watford WD24
4QN. Tel. (0117) 921 72 41. E-mail: marnie.watkins@nhsbt.nhs.uk. Fax
(01454) 84 16 33.
Internet address(es):
General address of the contracting authority: www.blood.co.uk.
I.2) TYPE OF THE CONTRACTING AUTHORITY AND MAIN ACTIVITY OR ACTIVITIES:
Body governed by public law.
Health.
SECTION II: OBJECT OF THE CONTRACT
II.1) DESCRIPTION
II.1.1) Title attributed to the contract by the contracting authority:
Framework Agreement for the Supply of Prion Reduction Systems.
II.1.2) Type of contract and location of works, place of delivery or of
performance: Supplies.
Purchase.
Main place of delivery: UK.
II.1.4) Short description of the contract or purchase(s): The NHSBT
requires a Framework Agreement for the Supply of Systems for the removal
of Infectious Prions from Whole Blood and/or Red Cells for Transfusion.
Due to the new and still emerging technologies in this market the NHSBT
requires potential suppliers to submit their systems for independent
evaluation of efficacy. To be considered for this programme of independent
evaluation, data must be supplied as outlined below. Following initial
review of the data the NHSBT will issue an Invitation to Tender in 1st
August 2007 to participating suppliers. A Framework Agreement will be
issued to successful supplier(s) in 1st Januray 2008 and will be followed
by a mini-tender against the Framework prior to purchase of systems as
required. Supplies under this Framework will only take place if an
instruction from the Department of Health is received to implement the
technology. The closing date for consideration and submission of such data
is 17th July 2007. To be considered for the independent evaluation, the
following data needs to be submitted: • Demonstration of a minimum of 3
log reduction in infectivity in brain homogenate spike studies and >1 log
reduction (to the limit of detection) in endogenous infectivity studies.
Suppliers will also need to state their position with regard to CE
marking. • Demonstration that data from prototypic devices translates to
the clinical device. In addition, suppliers will also need to provide
evidence of the following: • Assessment of system variables: Suppliers
should demonstrate the efficacy of the process under two sets of
conditions, blood which has been stored at 4ºC and at ambient temperature.
• Process control: The companies should propose suitable surrogate markers
to apply statistical process control over the prion reduction systems. •
Extension of study to plasma and platelet concentrates: At present prion
reduction systems are only applicable to red cell concentrates. The
extension of this work to whole blood, platelet and plasma concentrates is
encouraged. The NHSBT recognises this is new technology and suppliers who
do not necessarily meet all of our requirements at this stage or who are
unable to provide all the data can be considered at a later date since we
will be repeating this Framework approach during 2008. Technical Capacity:
Suppliers also need to submit a list of technical facilities, audit
standards, production capacities & control measures. Duration of the
Framework Agreement: 4 years Commencement of Framework Agreement: 1st
January 2008 Award Criteria: for example, Quality – 30 %, Technical
Specification – 40 %, Cost –20 %, Delivery – 10 %.
II.1.5) Common procurement vocabulary (CPV): 33100000.
II.1.6) Contract covered by the Government Procurement Agreement (GPA):
No.
II.2) TOTAL FINAL VALUE OF CONTRACT(S)
II.2.1) Total final value of contract(s): Value: 20 000 000 GBP.
SECTION IV: PROCEDURE
IV.1) TYPE OF PROCEDURE
IV.1.1) Type of procedure: Restricted.
IV.2) AWARD CRITERIA
IV.2.1) Award criteria: The most economically advantageous tender in
terms of
1. Technical Specification. Weighting: 40.
2. Quality. Weighting: 30.
3. Cost. Weighting: 20.
4. Delivery. Weighting: 10.
IV.2.2) An electronic auction was used: No.
IV.3) ADMINISTRATIVE INFORMATION
IV.3.1) File reference number attributed by the Contracting Authority:
NBS0896/G/AP.
IV.3.2) Previous publication(s) concerning the same contract: Contract
notice
Notice number in OJ: 2007/S 110-135802 of 12.6.2007.
SECTION V: AWARD OF CONTRACT
CONTRACT NO: NBS0896/G/AP
TITLE: Framework Agreement for the Supply of Prion Reduction Systems.
V.1) DATE OF CONTRACT AWARD: 10.3.2008.
V.2) NUMBER OF OFFERS RECEIVED: 1.
V.3) NAME AND ADDRESS OF ECONOMIC OPERATOR TO WHOM THE CONTRACT HAS BEEN
AWARDED: MacoPharma (UK) Ltd, 8th Floor Regal House 70 London Road,
UK-Twickenham TW1 3QS. E-mail: belinda.larby@macopharma.co.uk.
V.4) INFORMATION ON VALUE OF CONTRACT Initial estimated total value of
the contract:
Value: 20 000 000 GBP.
Excluding VAT.
V.5) THE CONTRACT IS LIKELY TO BE SUB-CONTRACTED: No.
SECTION VI: COMPLEMENTARY INFORMATION
VI.1) CONTRACT RELATED TO A PROJECT AND/OR PROGRAMME FINANCED BY
COMMUNITY FUNDS: No.
VI.4) DATE OF DISPATCH OF THIS NOTICE: 1.10.2008.
Please note that this notice is for your information only.
We try our best to have the most accurate and up-to-date information available on our web site, but we cannot guarantee that all of the information provided is error-free.
If you have any suggestions for updates/corrections for this notice, please let us know.